Anhui Wanbang Pharmaceutical Technology Co.,Ltd. — Investor Relations & Filings
Anhui Wanbang Pharmaceutical Technology Co., Ltd. is a comprehensive pharmaceutical research and development service provider specializing in clinical research and technical services. Operating primarily as a Contract Research Organization (CRO), the company offers a wide range of services including bioequivalence (BE) studies, Phase I through IV clinical trials, and pharmacokinetics (PK/PD) research. It provides end-to-end solutions for pharmaceutical development, encompassing clinical trial design, site management, data management, and statistical analysis. The firm focuses on supporting generic drug consistency evaluations and the development of innovative drugs. By maintaining advanced laboratory facilities and clinical research centers, the company ensures compliance with international quality standards and regulatory requirements to facilitate the market entry of diverse therapeutic products.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年度业绩预告 | 2026-01-30 | Chinese | |
| 关于公司控制的合伙企业认购私募基金份额的进展公告 | 2026-01-27 | Chinese | |
| 安徽承义律师事务所关于安徽万邦医药科技股份有限公司2026年第一次临时股东会的法律意见书 | 2026-01-14 | Chinese | |
| 2026年第一次临时股东会决议公告 | 2026-01-14 | Chinese | |
| 关于使用部分超募资金永久补充流动资金的公告 | 2025-12-25 | Chinese | |
| 关于召开2026年第一次临时股东会的通知 | 2025-12-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 39573354 | 2025年度业绩预告 | 2026-01-30 | Chinese | ||
| 39573347 | 关于公司控制的合伙企业认购私募基金份额的进展公告 | 2026-01-27 | Chinese | ||
| 39573340 | 安徽承义律师事务所关于安徽万邦医药科技股份有限公司2026年第一次临时股东会的法律意见书 | 2026-01-14 | Chinese | ||
| 39573333 | 2026年第一次临时股东会决议公告 | 2026-01-14 | Chinese | ||
|
2025
11 filings
| |||||
| 39573325 | 关于使用部分超募资金永久补充流动资金的公告 | 2025-12-25 | Chinese | ||
| 39573324 | 关于召开2026年第一次临时股东会的通知 | 2025-12-25 | Chinese | ||
| 39573323 | 第三届董事会第四次会议决议公告 | 2025-12-25 | Chinese | ||
| 39573322 | 国联民生证券承销保荐有限公司关于安徽万邦医药科技股份有限公司使用部分闲置募集资金(含超募资金)及自有资金进行现金管理的核查意见 | 2025-12-25 | Chinese | ||
| 39573320 | 关于使用部分闲置募集资金(含超募资金)及自有资金进行现金管理的公告 | 2025-12-25 | Chinese | ||
| 39573317 | 董事和高级管理人员离职管理制度 | 2025-12-25 | Chinese | ||
| 39573315 | 董事和高级管理人员持有和买卖本公司股票管理制度 | 2025-12-25 | Chinese | ||
| 39573313 | 董事和高级管理人员薪酬管理制度 | 2025-12-25 | Chinese | ||
| 39573312 | 国联民生证券承销保荐有限公司关于安徽万邦医药科技股份有限公司使用部分超募资金永久补充流动资金的核查意见 | 2025-12-25 | Chinese | ||
| 39573310 | 关于使用部分闲置募集资金(含超募资金)及闲置自有资金购买现金管理产品到期赎回并继续购买现金管理产品的进展公告 | 2025-12-24 | Chinese | ||
| 39573307 | 关于公司控制的合伙企业认购私募基金份额的公告 | 2025-12-22 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Anhui Wanbang Pharmaceutical Technology Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56338/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56338 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56338 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56338 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56338}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (id: 56338)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.